Nerlynx (neratinib) — Medica
Cervical cancer – recurrent or metastatic HER2-mutant disease
Initial criteria
- age ≥ 18 years
- HER2-mutant cervical cancer
- recurrent or metastatic disease
- has tried at least one systemic regimen (e.g., pembrolizumab, atezolizumab, cisplatin, paclitaxel, bevacizumab, topotecan, carboplatin)
Approval duration
1 year